



## **ASX Announcement**

### **Victor Windeyer appointed General Manager of Sunshine Heart Company Pty Ltd**

**Sydney Australia 30 May 2007:** Sunshine Heart (ASX:SHC) today announced the appointment of Mr Victor Windeyer as General Manager of Sunshine Heart Company Pty Ltd (SHPL). SHPL is a wholly owned subsidiary of Sunshine Heart, Inc (SHC). Mr Windeyer will continue in his role as Chief Operating Officer (COO) of Sunshine Heart Inc.

The appointment of Mr Windeyer as SHPL's General Manager is recognition of the critical role of the Sydney-based operation within the operational and regulatory structure of SHC. Mr Windeyer joined Sunshine Heart in January 2006 after spending several years in a related role with another heart failure device company, Ventracor Ltd (VCR). At VCR, he was Program Manager for the VentrAssist Left Ventricular Assist Device. In addition, he has had experience in project management with Invetech Pty Ltd where he led a team developing a novel product in the histology market. Mr Windeyer has also worked as a mechanical engineer for Cochlear Limited, after graduating with a degree in Mechatronic Engineering from the University of Sydney.

"Victor has been a great asset to Sunshine Heart with his experience in medical device development as well as heart assist devices." said Sunshine Heart's CEO, Don Rohrbaugh. "This promotion will properly position Victor within the SHC organization and recognizes his significant contribution in the Company's recent advances towards initiating the US clinical trials". In this role he will be responsible for leadership of the growing Sunshine Heart team within Australia.

Victor Windeyer, along with CFO Brian Bolton, will continue to report to the CEO, Don Rohrbaugh, who is located at the company's Orange County, California office. Victor will concentrate on leadership of the Australian operations allowing the CEO to concentrate on strategic relationships and managing the commencement of the US clinical trial.

"I am looking forward to commencing my expanded role within Sunshine Heart" said Victor Windeyer. "It is very exciting to be part of the SHC team advancing an entirely new form of heart assist device onto the world market."

"Sunshine Heart is now positioned to achieve significant Company milestones" said Chairman, Malcolm McComas. "We have the new wearable C-Pulse™ Driver, a great group of US university-based teaching hospitals and will shortly submit the IDE request to the FDA to initiate the US clinical trial of the C-Pulse™ System in the second half of 2007."

For further information, please visit [www.sunshineheart.com](http://www.sunshineheart.com) or contact:

**Media**

Daniella Goldberg PhD  
+612 9237 2803 / 0416 211 067  
[dgoldberg@bcg.com.au](mailto:dgoldberg@bcg.com.au)

**Sunshine Heart**

Victor Windeyer  
Chief Operating Officer  
+61 2 8424 7700  
[victor.windeyer@sunshineheart.com](mailto:victor.windeyer@sunshineheart.com)

Don Rohrbaugh  
Chief Executive Officer  
+1 714 665 1951  
[don.rohrbaugh@sunshineheart.com](mailto:don.rohrbaugh@sunshineheart.com)

Brian Bolton  
Chief Financial Officer  
+61 2 8424 7700  
[brian.bolton@sunshineheart.com](mailto:brian.bolton@sunshineheart.com)

**About the C-Pulse™ System**

Sunshine Heart's C-Pulse™ System is an implantable, non-blood contacting heart assist device powered by an external driver unit. The implantable cuff is inflated and deflated rhythmically to improve blood supply to the heart and body as well as reduce the workload of the heart.

Sunshine Heart (ASX: SHC) ([www.sunshineheart.com](http://www.sunshineheart.com)) is a global medical device company, currently planning to initiate US clinical trials of the C-Pulse™ System in the second half of 2007 for the treatment of people with moderate heart failure (HF); people that have a debilitating poor quality of life. C-Pulse™ is uniquely designed as a cost effective device to serve this HF patient population which has been estimated by Sunshine Heart to be nearly 1 million patients in the USA alone.

C-Pulse™ is clinically positioned between CRT pacemakers and mechanical left ventricular assist devices (LVADs). C-Pulse™ is targeted to be used in Class III HF patients to safely and cost effectively reduce heart failure complications. Many of these patients have become refractory to drugs or no longer receive symptom relief with pacemakers and are too healthy for LVADS and heart transplant. Unlike other current treatments, C-Pulse™ has no blood contact, a uniquely differentiating feature. Initial clinical data indicates that C-Pulse™ increases coronary blood flow, reduces the workload of the native heart and allows the patient to electively turn the device off and on for patient convenience. A proprietary wearable driver powers the C-Pulse™ device and allows freedom of movement for these HF patients. These unique features have been demonstrated in human clinical experiences in Australia and New Zealand.

Sunshine Heart listed on the ASX in September 2004 and has a presence in Australia, New Zealand and the United States of America.

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Stock Exchange.